• |
  • |
  • |
  • |
Donate

Project

PHARM - A phase 4, randomized, double-blind, multicenter, parallel group, active-controlled, dose-optimization safety and efficacy study of SPD489 (Vy

Center:
Fiscal Year:
2013
Contact Information:
Project Description:
A phase 4, randomized, double-blind, multicenter, parallel group, active-controlled, dose-optimization safety and efficacy study of SPD489 (Vyvanse) compared with OROS-MPH (Concerta) with a placebo reference arm, in adolescents aged 13-17 years
Keyword(s):
Core Function(s):
Performing Research or Evaluation
Area of Emphasis
Health-Related Activities
Target Audience:
Professionals and Para-Professionals, General Public
Unserved or Under-served Populations:
Specific Groups
Primary Target Audience Geographic Descriptor:
International
Funding Source:
COVID-19 Related Data:
N/A